Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 15, 2015, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $81.85 to $422,748,916.10.

Highlighted Stocks Traded by Insiders:

JPMorgan Chase (JPM) - FREE Research Report

Cutler Stephen M, who is General Counsel at JPMorgan Chase, sold 18,617 shares at $64.09 on April 15, 2015. Following this transaction, the General Counsel owned 206,867 shares meaning that the stake was reduced by 8.26% with the 18,617-share transaction.

Zames Matthew E, who is Chief Operating Officer at JPMorgan Chase, sold 4,258 shares at $64.08 on April 15, 2015. Following this transaction, the Chief Operating Officer owned 233,154 shares meaning that the stake was reduced by 1.79% with the 4,258-share transaction.

The shares most recently traded at $64.12, up $0.04, or 0.07% since the insider transaction. Historical insider transactions for JPMorgan Chase go as follows:

  • 4-Week # shares bought: 9,050
  • 4-Week # shares sold: 2,826
  • 12-Week # shares bought: 9,050
  • 12-Week # shares sold: 236,374
  • 24-Week # shares bought: 9,050
  • 24-Week # shares sold: 237,518

The average volume for JPMorgan Chase has been 16.6 million shares per day over the past 30 days. JPMorgan Chase has a market cap of $234.1 billion and is part of the financial sector and banking industry. Shares are up 2.6% year-to-date as of the close of trading on Wednesday.

JPMorgan Chase & Co., a financial holding company, provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Management. The stock currently has a dividend yield of 2.54%. The company has a P/E ratio of 11.9. Currently, there are 16 analysts who rate JPMorgan Chase a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JPM - FREE

TheStreet Quant Ratings rates JPMorgan Chase as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full JPMorgan Chase Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alimera (ALIM) - FREE Research Report

Bavp, L.P., who is 10% Owner at Alimera, sold 35,800 shares at $5.03 on April 15, 2015. Following this transaction, the 10% Owner owned 4.5 million shares meaning that the stake was reduced by 0.79% with the 35,800-share transaction.

The shares most recently traded at $5.00, down $0.03, or 0.67% since the insider transaction. Historical insider transactions for Alimera go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 12,000

The average volume for Alimera has been 156,900 shares per day over the past 30 days. Alimera has a market cap of $224.0 million and is part of the health care sector and drugs industry. Shares are down 8.84% year-to-date as of the close of trading on Wednesday.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina. Currently, there are 2 analysts who rate Alimera a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALIM - FREE

TheStreet Quant Ratings rates Alimera as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Alimera Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cardtronics (CATM) - FREE Research Report

Brewster J Chris, who is Chief Financial Officer at Cardtronics, sold 7,000 shares at $38.66 on April 15, 2015. Following this transaction, the Chief Financial Officer owned 64,825 shares meaning that the stake was reduced by 9.75% with the 7,000-share transaction.

The shares most recently traded at $39.65, up $0.99, or 2.49% since the insider transaction. Historical insider transactions for Cardtronics go as follows:

  • 4-Week # shares bought: 7,800
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 7,800
  • 12-Week # shares sold: 21,275
  • 24-Week # shares bought: 7,800
  • 24-Week # shares sold: 81,275

The average volume for Cardtronics has been 303,900 shares per day over the past 30 days. Cardtronics has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are up 3.34% year-to-date as of the close of trading on Wednesday.

Cardtronics, Inc. provides automated consumer financial services through its network of automated teller machines (ATMs) and multi-function financial services kiosks. It operates through U.S., Europe, and Other International segments. The company has a P/E ratio of 48.1. Currently, there are 8 analysts who rate Cardtronics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CATM - FREE

TheStreet Quant Ratings rates Cardtronics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and poor profit margins. Get the full Cardtronics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null